Development and validation of a serum proteomic test for predicting patient outcomes in advanced non-small cell lung cancer treated with atezolizumab or docetaxel
Aspects of host immune response to disease can be assessed from the circulating proteome and provide outcome stratification for patients treated with atezolizumab. Combining this information with PD-L1 measurements improves prediction of outcomes.
Authors
- Laura Maguire
- Heinrich Röder (ORCID: https://orcid.org/0000-0003-1860-2491)
- Patrick Norman
- Mark L. McCleland
- Lelia Net
- David S. Shames (ORCID: https://orcid.org/0000-0002-5900-1177)
- Minu K. Srivastava (ORCID: https://orcid.org/0009-0000-3827-9180)
- Joanna Roder
- Robert W. Georgantas (ORCID: https://orcid.org/0000-0002-5187-1485)
- Senait Asmellash
- Wei Zou (ORCID: https://orcid.org/0000-0001-5307-4685)
Institutions
- Gene Therapy Laboratory (FR)
- Cancer Research And Biostatistics (US)
- Helix Biomedix (United States) (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1136/jitc-2024-010578
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05